|
||||||||||||||||||||||
|
|
Phase III Large Dose/Fraction Radiotherapy and Hypoxic Cell Sensitizer Misonidazole for Advanced Carcinoma of the Uterine Cervix
Basic Trial Information
Objectives I. Increase palliative effect, local control of disease, and rate of survival in patients with advanced cervical carcinoma. Entry Criteria Disease Characteristics: See General Eligibility Criteria Patient Characteristics: See General Eligibility Criteria General Eligibility Criteria: Patients with advanced uterine cervix cancer with massive disease in the pelvis, who are not candidates for conventional radiotherapy. Expected Enrollment 10 to 15 patients per year will be entered. Protocol closed. Outline Randomized study. Arm I: Radiotherapy. Tumor irradiation. Arm II: Radiotherapy plus Hypoxic Cell Sensitization. Tumor irradiation plus Misonidazole, MNI, NSC-261037. Trial Lead Organizations M. D. Anderson Cancer Center at University of Texas
Note: The purpose of most clinical trials listed in this database is to test new cancer treatments, or new methods of diagnosing, screening, or preventing cancer. Because all potentially harmful side effects are not known before a trial is conducted, dose and schedule modifications may be required for participants if they develop side effects from the treatment or test. The therapy or test described in this clinical trial is intended for use by clinical oncologists in carefully structured settings, and may not prove to be more effective than standard treatment. A responsible investigator associated with this clinical trial should be consulted before using this protocol. |
NCI Home |
Images Version |
Contact Us |
Policies |
Accessibility |
Viewing Files |
FOIA |
Site Help |
Site Map
|
A Service of the National Cancer Institute |